|Bid||76.02 x 2200|
|Ask||76.37 x 3000|
|Day's Range||75.34 - 77.15|
|52 Week Range||53.22 - 78.47|
|Beta (5Y Monthly)||0.54|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 27, 2022 - May 02, 2022|
|Forward Dividend & Yield||2.16 (2.85%)|
|Ex-Dividend Date||Mar 31, 2022|
|1y Target Est||79.16|
As the leader in medical diagnostics, Roche (OTC: RHHB.F) acted quickly to deliver valuable COVID-19 screening tests to the marketplace. Assisted by COVID-related sales, its diagnostics division is now delivering stronger growth than its larger pharmaceuticals division. Roche's medical diagnostics division saw strong growth throughout 2021 and into the begining of 2022.
Merck's (MRK) anti-PD-1 therapy Keytruda nears potential approval as an adjuvant treatment for adolescent pediatric patients with stage IIB, IIC or III melanoma following complete resection.
Long-term agreement will enable the continued development and eventual construction and operation of the Texas solar park that will annually power the equivalent of more than 37,000 average homes